Highly selective beta-blockers are effective and generally safe for pregnant women with cardiovascular diseases, though fetal and newborn monitoring is recommended due to rare side effects.
Supports consideration in pregnant patients with monitoring; leaves open need for randomized confirmation.
Highly selective β-adrenoblockers (β-AB) are used in pregnant women with cardiovascular diseases (arterial hypertension, arrhythmia, Marfan syndrome, hypertrophic cardiomyopathy). β-AB fall into the category C according to safety classification of Food and Drug Administration (US FDA). Their prescription in different clinical situations meets the principle of "risk–benefit". Fetus and newborn status should be monitored because β-AB can cause bradycardia, hypoglycemia, apnea and metabolic disorders. The risk of these side effects is extremely low, while β-AB clinical efficacy is high.
No takes yet. Share an insight, caveat, or question.
Стрюк et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: